Shakeya Allen was 27 years old when she felt something was not right with her health. A miscarriage would lead to her diagnosis. “They said, ‘Don’t worry. Women under 40 do not get uterine cancer.
The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...
Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...
Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
National Cancer Awareness Month provides an opportunity for the medical community to spotlight the ongoing battle against one ...
Managing endometrial cancer can be very stressful. Taking steps to support your emotional and mental health is important for improving your quality of life with this condition. An endometrial ...
Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback